Applications can only reach 8 %~15 % of utilization on modern computer systems. There are many obstacles to improving system efficiency. The key root is the conflict between the fixed general computer architecture and...Applications can only reach 8 %~15 % of utilization on modern computer systems. There are many obstacles to improving system efficiency. The key root is the conflict between the fixed general computer architecture and the variable requirements of applications. Proactive reconfigurable computing architecture(PRCA) is proposed to improve computing efficiency. PRCA dynamically constructs an efficient computing architecture for a specific application via reconfigurable technology by perceiving requirements,workload and utilization of computing resources. Proactive decision support system(PDSS),hybrid reconfigurable computing array(HRCA) and reconfigurable interconnect(RIC) are intensively researched as the key technologies. The principles of PRCA have been verified with four applications on a test bed. It is shown that PRCA is feasible and highly efficient.展开更多
BACKGROUND Allogeneic hematopoietic stem cell transplantation(Allo-HSCT)is currently the only viable method of curing patients with acute myeloid leukaemia.In 30%to 50%of patients,donors and recipients have some level...BACKGROUND Allogeneic hematopoietic stem cell transplantation(Allo-HSCT)is currently the only viable method of curing patients with acute myeloid leukaemia.In 30%to 50%of patients,donors and recipients have some level of ABO blood group incompatibility.ABO blood group incompatibility can cause antibodies against the donor's red blood cells to persist in the recipient's body,resulting in a delay of several months in the recovery of red blood cells.A number of different treatments have been reported for post-transplant pure red cell aplastic anaemia(PRCA),such as plasmapheresis,donor lymphocyte infusions,anti-thymocyte globulin,rituximab and steroids.CASE SUMMARY A 41-year-old female diagnosed with acute myeloid leukaemia underwent peripheral blood allogeneic haematopoietic stem cell transplantation in November 2013 from an HLA matched unrelated donor.The donor was AB-positive and the recipient was O-positive.The patient was diagnosed with PRCA three months after receiving the donor stem cell transplant.After failing multiple lines of therapy,the patient applied for daratumumab.After receiving three doses of daratumumab,the patient developed a reticulocyte response and no longer required CONCLUSION The use of daratumumab anti-CD38 for the remove of plasma cells is safe and effective and may be tried for refractory patients with PRCA after undergoing allo-HSCT for ABO incompatibility.展开更多
抗EPO抗体相关纯红细胞再生障碍性贫血是一种应用重组人促红细胞生成素(recombinant human erythropoietin,rHuEPO)而引起的纯红细胞再生障碍性贫血(pure red cell aplasia,PRCA),临床上比较少见,其主要特点为rHuEPO治疗无效,呈进行性贫...抗EPO抗体相关纯红细胞再生障碍性贫血是一种应用重组人促红细胞生成素(recombinant human erythropoietin,rHuEPO)而引起的纯红细胞再生障碍性贫血(pure red cell aplasia,PRCA),临床上比较少见,其主要特点为rHuEPO治疗无效,呈进行性贫血,特点为外周血中网织红细胞及骨髓中红系前体细胞绝对缺乏,而粒系和巨核系细胞数正常。展开更多
文摘Applications can only reach 8 %~15 % of utilization on modern computer systems. There are many obstacles to improving system efficiency. The key root is the conflict between the fixed general computer architecture and the variable requirements of applications. Proactive reconfigurable computing architecture(PRCA) is proposed to improve computing efficiency. PRCA dynamically constructs an efficient computing architecture for a specific application via reconfigurable technology by perceiving requirements,workload and utilization of computing resources. Proactive decision support system(PDSS),hybrid reconfigurable computing array(HRCA) and reconfigurable interconnect(RIC) are intensively researched as the key technologies. The principles of PRCA have been verified with four applications on a test bed. It is shown that PRCA is feasible and highly efficient.
基金Natural Science Foundation of Guizhou Province,China,No.397.
文摘BACKGROUND Allogeneic hematopoietic stem cell transplantation(Allo-HSCT)is currently the only viable method of curing patients with acute myeloid leukaemia.In 30%to 50%of patients,donors and recipients have some level of ABO blood group incompatibility.ABO blood group incompatibility can cause antibodies against the donor's red blood cells to persist in the recipient's body,resulting in a delay of several months in the recovery of red blood cells.A number of different treatments have been reported for post-transplant pure red cell aplastic anaemia(PRCA),such as plasmapheresis,donor lymphocyte infusions,anti-thymocyte globulin,rituximab and steroids.CASE SUMMARY A 41-year-old female diagnosed with acute myeloid leukaemia underwent peripheral blood allogeneic haematopoietic stem cell transplantation in November 2013 from an HLA matched unrelated donor.The donor was AB-positive and the recipient was O-positive.The patient was diagnosed with PRCA three months after receiving the donor stem cell transplant.After failing multiple lines of therapy,the patient applied for daratumumab.After receiving three doses of daratumumab,the patient developed a reticulocyte response and no longer required CONCLUSION The use of daratumumab anti-CD38 for the remove of plasma cells is safe and effective and may be tried for refractory patients with PRCA after undergoing allo-HSCT for ABO incompatibility.
文摘抗EPO抗体相关纯红细胞再生障碍性贫血是一种应用重组人促红细胞生成素(recombinant human erythropoietin,rHuEPO)而引起的纯红细胞再生障碍性贫血(pure red cell aplasia,PRCA),临床上比较少见,其主要特点为rHuEPO治疗无效,呈进行性贫血,特点为外周血中网织红细胞及骨髓中红系前体细胞绝对缺乏,而粒系和巨核系细胞数正常。
